The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of combination of radiotherapy with pembrolizumab plus chemotherapy in patients with previously untreated metastatic non-small cell lung cancer: North Japan Lung Cancer Study Group 1902.
 
Taku Nakagawa
Honoraria - AstraZeneca; Chugai Pharma; Japan Blood Products Organization; Lilly Japan; MSD K.K; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Yoko Tsukita
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Lilly; MSD; Nippon Boehringer Ingelheim; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca
Research Funding - Chugai Pharma (Inst); Lilly (Inst)
 
Rei Umezawa
No Relationships to Disclose
 
Akira Anbai
No Relationships to Disclose
 
Tomonori Makiguchi
Honoraria - Asahi Kasei; AstraZeneca; Chugai Pharma; GlaxoSmithKline; Lilly; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
 
Hisashi Tanaka
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Ono Pharmaceutical; Pfizer
 
Yosuke Horii
No Relationships to Disclose
 
Aya Suzuki
No Relationships to Disclose
 
Ryo Morita
No Relationships to Disclose
 
Hitomi Nogawa
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Novartis; Pfizer; Takeda
 
Hiroshi Yokouchi
Honoraria - AstraZeneca; Chugai Pharma
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Nozomu Kimura
No Relationships to Disclose
 
Keiichi Jingu
Research Funding - Elekta (Inst)
 
Akira Inoue
Honoraria - AstraZeneca; Daiichi Sankyo
 
Hisatoshi Sugiura
No Relationships to Disclose
 
Eisaku Miyauchi
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Meyers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kyorin; Kyowa Kirin; Kyowa Kirin Co Ltd; Lilly; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Boehringer Ingelheim; Daiichi Sankyo KK; Merck; Ono Pharmaceutical